SCHEMBL24089955

SCHEMBL24089955

CC(C)c1ccc2nc(Nc3ccc(Cl)cc3)n(-c3ccccc3)c(=O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JUN P05412 2/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
KDM1A O60341 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 2/20 0.40
HTR6 P50406 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
GAA P10253 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24090148 0.92 HSD17B10 (0.45) KDM1AHSD17B10
SCHEMBL24090094 0.87 TP53 (0.48) JUNNFKB1NFKB2RELASMN1; SMN2
SCHEMBL29623326 0.87 TP53 (0.48) JUNNFKB1NFKB2RELASMN1; SMN2
SCHEMBL24089985 0.87 KDM1A (0.42) KDM1AALDH1A1
SCHEMBL24089905 0.85 KDM1A (0.44) KDM1AKDM4E
SCHEMBL24090111 0.84 KDM1A (0.42) KDM1AMEN1ALDH1A1KMT2A
SCHEMBL24089978 0.84 TUBB4A (0.48) SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL24089982 0.83 JUN (0.45) JUNNFKB1NFKB2RELASMN1; SMN2
SCHEMBL24089904 0.81 DHODH (0.43) JUNNFKB1NFKB2RELA
SCHEMBL23958213 0.81 TUBB4A (0.41) JUNNFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL JUN 2711/4885NFKB1 2159/4885NFKB2 1725/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 JUN 2410/4885NFKB1 2523/4885NFKB2 1785/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 JUN 2410/4885NFKB1 2523/4885NFKB2 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.